Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and ...

Simultaneously, BGLC has obtained exclusive, perpetual rights to manufacture, market, and distribute VitaGuard™ across all ASEAN markets, solidifying the Company as the sole provider of this advanced ...

Being selected to give an oral presentation at ASH is a tremendous honor and a major milestone,” said Sanjeev Luther, President & CEO of Ernexa Therapeutics. “It’s a recognition of the potential of ...

Nationally nearly half of all Medicare Advantage enrollees are now eligible for prior authorization and reimbursement for ReWalk 7,” said Mark Grant, CEO of Lifeward. “This prior authorization ...

About NKGen Biotech, Inc. NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is ...

A long-time user of Commure’s charge capture technology, OBHG is rapidly scaling Commure Autonomous Coding across its hospital footprint. The results are striking: within three months, clinicians ...

About QHSLab QHSLab, Inc. (OTCQB: USAQ) is a digital health technology leader providing preventive screening, assessment, and workflow solutions for primary care providers. Its tools help practices ...

Based on the FDA’s Pre-NDA meeting written response, the Company concludes that the objectives of the pre-NDA meeting have been accomplished and has determined that the in-person meeting, originally ...

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim data from the ...

At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago, IL, Biodesix will present new findings on its on-market Nodify Lung ® tests, with data that spotlight the ...

IV Sapu003 Reduces GI Exposure to Everolimus by 67-Fold Compared With Oral Dosing ...

Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio @ IBN ( InvestorBrandNetwork), a ...